Views & Analysis | Perspectives on pharma industry issues

Oncology

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Digital

Building agentic AI in healthcare

Healthcare organisations can’t afford to ignore agentic AI, but they also can’t afford to deploy it without the infrastructure to use it responsibly.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

R&D

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.

Views & Analysis

It’s time to tackle the gender health gap with technology

The potential for technology to transform the way we deliver healthcare is nothing new.

Views & Analysis

Rethinking trial engagement and recruitment starts with pati...

With countless media stories regarding COVID-19 published over a period of several years, it was obvious that people around the globe were tuned in to every step of the fight against the pa

Oncology

A history of blood cancer treatment

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to other types of the disease.

Sales & Marketing

Why trust is becoming pharma’s most important visibility met...

Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.

Sales & Marketing

Pharma is marketing to the wrong mind

On the benefits of instinctive marketing, over either rational or emotional.

Digital

Building agentic AI in healthcare

Healthcare organisations can’t afford to ignore agentic AI, but they also can’t afford to deploy it without the infrastructure to use it responsibly.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Oncology

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Oncology

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Patients